Literature DB >> 26799185

Molecular control of non-muscle myosin II assembly.

Alba Juanes-García, Clara Llorente-González, Miguel Vicente-Manzanares1.   

Abstract

Entities:  

Keywords:  actin; migration; myosin; polarity

Mesh:

Substances:

Year:  2016        PMID: 26799185      PMCID: PMC4868672          DOI: 10.18632/oncotarget.6936

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


× No keyword cloud information.
Mechanical forces play fundamental roles in cellular processes related to movement. The major generator of mechanical forces in living systems is myosin II, which lies inside cells. Myosin II propels actin filament sliding, converting chemical energy into movement in various scales, from stress fibre formation and sliding to muscle contraction. In non-muscle cells, such forces are exerted at a cellular/subcellular scale and drive motility processes, e.g. cell migration, division, etc. There are several isoforms of myosin II, divided into muscle, smooth muscle and non-muscle. They all consist of a hexamer made of two heavy chains (MHCII) and four light chains, two structural (ELC) and two regulatory (RLC). The heavy chain displays three domains: a globular, actin- and ATP-binding domain, a supercoiled long domain that mediates dimerization of the MHCII; and a non-helical tail domain. Non-muscle myosin II (NMII) appears as three isoforms, II-A, II-B and II-C depending on the MHCII. Their ability to generate mechanical forces is context-dependent, thereby each isoform regulates specific cellular functions. In addition, every cell type displays a specific pattern of expression that may evolve over time, e.g. during embryogenesis, being crucial for proper development. Of the three isoforms, NMII-A is the fastest moving, although it can bear considerably less load than the other two. It displays fast assembly immediately behind the leading edge of migrating cells. Conversely, NMII-B and II-C are slower, but bear more load [1]. NMII-B assembles slowly in central, lateral and back regions of the cell and use pre-formed NMII-A-based filaments for their elongation. Selective depletion experiments have revealed specific cellular roles for these isoforms. NMII-A depletion impairs focal adhesion formation and retraction of the rear, whereas NMII-B depletion causes a marked loss of front-rear polarity in 2-D [2]. When not forming filaments, NMII is folded in a compact, assembly-incompetent conformation (10S) that extends by phosphorylation of the RLC on Ser19. The same phosphorylation triggers the conformational movement of the head of the heavy chain that enables actin filament movement [3]. Another level of regulation resides in the stability of the filaments that is controlled by the 10S-6S balance and the ability of the hexamers to form oligomers (mini-filaments) of 6-25 hexamers arrayed in an anti-parallel fashion [2]. A regulatory hotspot of the stability of the oligomers is the phosphorylation of the heavy chain. Unlike RLC phosphorylation, this is an isoform-specific mechanism. For example, the stability of the NMII-A filaments is controlled by phosphorylation of MHCII-A on S1943. Phospho-S1943 NMII-Amini-filaments are unstable, thus forming very small and weak filaments, and overall loss of cellular contraction [4]. Regarding NMII-B, S1935 is a novel phospho-regulatory residue that controls the dynamics of NMII-B filaments. When phosphorylated, NMII-B forms smaller mini-filaments that bear less load. In fact, assembled phospho-Ser1935 NMII-B behaves like assembled NMII-A, including its ability to nucleate mini-filaments de novo [5]. This motifis crucially important for the speed and load of the NMII isoforms, since its “transplantation” into the same spot in NMII-A endows it with NMII-B-like properties (larger filaments, higher load and decreased de novo mini-filament formation). S1935 is much closer to the domain-breaking Pro in NMII-B than S1943 is in NMII-A, suggesting different mechanisms that nevertheless have a similar outcome, i.e. decreased filament stability. In the case of NMII-A, S1943 phosphorylation regulates its interaction with S100A4/Mts1, which may control NMII-A assembly dynamics and stability [4]. We speculate that addition of a strong negative charge due to phosphorylation of S1935 next to the domain-breaking Pro (1933) compromises the stability of the bundled coiled-coil + non-helical domain pieces of NMII-B. As a consequence, filaments are less stably packed which may cause higher filament turnover disassembly. At a cellular level, a phosphomimetic mutation of S1935 impairs formation of the large actomyosin budles that define the backof the cell and a concomitant loss of directional polarity in 2-D, indicating that S1935 controls the formation of a stable directional rear that supports polarized migration [2]. The physiological implications of these mechanisms of regulation are just beginning to be elucidated. Phosphorylation of S1943 controls CD34+ hematopoietic stem cell fate [6]. Also, an inhibitory peptide from Met aminopeptidase-2 blocks the interaction of Mts1 with NMII-A, increasing NMII-A assembly and preventing tumor angiogenesis [7]. Whether S1935 phosphorylation directly controls the assembly of NMII-B or it does it by managing the interaction of NMII-B with accessory proteins remains to be shown. These studies suggest that the selective control of NMII assembly in an isoform-dependent manner is a central issue in processes involving symmetry breaking, motility and cell division.
  7 in total

Review 1.  Regulation of the function of mammalian myosin and its conformational change.

Authors:  Mitsuo Ikebe
Journal:  Biochem Biophys Res Commun       Date:  2008-01-22       Impact factor: 3.575

2.  Regulation of myosin-IIA assembly and Mts1 binding by heavy chain phosphorylation.

Authors:  Natalya G Dulyaninova; Vladimir N Malashkevich; Steven C Almo; Anne R Bresnick
Journal:  Biochemistry       Date:  2005-05-10       Impact factor: 3.162

3.  Disease-associated mutations and alternative splicing alter the enzymatic and motile activity of nonmuscle myosins II-B and II-C.

Authors:  Kye-Young Kim; Mihály Kovács; Sachiyo Kawamoto; James R Sellers; Robert S Adelstein
Journal:  J Biol Chem       Date:  2005-04-20       Impact factor: 5.157

4.  Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells.

Authors:  Jae-Won Shin; Amnon Buxboim; Kyle R Spinler; Joe Swift; David A Christian; Christopher A Hunter; Catherine Léon; Christian Gachet; P C Dave P Dingal; Irena L Ivanovska; Florian Rehfeldt; Joel Anne Chasis; Dennis E Discher
Journal:  Cell Stem Cell       Date:  2013-11-21       Impact factor: 24.633

Review 5.  Myosin II in mechanotransduction: master and commander of cell migration, morphogenesis, and cancer.

Authors:  Rocío Aguilar-Cuenca; Alba Juanes-García; Miguel Vicente-Manzanares
Journal:  Cell Mol Life Sci       Date:  2013-08-11       Impact factor: 9.261

6.  Efficient inhibition of tumor angiogenesis and growth by a synthetic peptide blocking S100A4-methionine aminopeptidase 2 interaction.

Authors:  Takahiro Ochiya; Keizo Takenaga; Masataka Asagiri; Kazumi Nakano; Hitoshi Satoh; Toshiki Watanabe; Shinobu Imajoh-Ohmi; Hideya Endo
Journal:  Mol Ther Methods Clin Dev       Date:  2015-04-01       Impact factor: 6.698

7.  A regulatory motif in nonmuscle myosin II-B regulates its role in migratory front-back polarity.

Authors:  Alba Juanes-Garcia; Jessica R Chapman; Rocio Aguilar-Cuenca; Cristina Delgado-Arevalo; Jennifer Hodges; Leanna A Whitmore; Jeffrey Shabanowitz; Donald F Hunt; Alan Rick Horwitz; Miguel Vicente-Manzanares
Journal:  J Cell Biol       Date:  2015-04-13       Impact factor: 10.539

  7 in total
  1 in total

1.  The Myosin II Inhibitor, Blebbistatin, Ameliorates FeCl3-induced Arterial Thrombosis via the GSK3β-NF-κB Pathway.

Authors:  Yuanyuan Zhang; Long Li; Yazheng Zhao; Han Han; Yang Hu; Di Liang; Boyang Yu; Junping Kou
Journal:  Int J Biol Sci       Date:  2017-05-15       Impact factor: 6.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.